Premium
Synergism of recombinant human interferon gamma with liposome‐encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes
Author(s) -
Sone Saburo,
Tandon Priti,
Utsugi Teruhiro,
Ogawara Mitsumasa,
Shimizu Eiji,
Nii Akihiko,
Ogura Takeshi
Publication year - 1986
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910380407
Subject(s) - liposome , tripeptide , recombinant dna , muramyl dipeptide , monocyte , in vitro , immunostimulant , interferon gamma , immunology , cytokine , pharmacology , chemistry , medicine , biochemistry , immune system , peptide , gene
Freshly isolated human peripheral blood monocytes from healthy volunteers are not cytotoxic to allogeneic A375 melanoma cells, but they were rendered tumoricidal by incubation in vitro with either liposomes containing 5 μg/μtmol phospholipid of muramyl tripeptide phosphatidylethanolamine (liposome‐MTP‐PE; optimal dose, 500 nmol/ml) or recombinant human interferon gamma (rIFN‐γ; optimal dose, 100 U/ml). A combination of sub‐threshold concentrations of liposome‐MTP‐PE (50 nmol/ml) and rIFN‐γ (1 or 10 U/ml) also induced significant tumor‐cell killing, indicating that the effects of rIFN‐γ and liposome‐MTP‐PE in monocyte activation are synergistic. In contrast to rIFN‐γ, recombinant INF‐α and IFN‐β had additive effects with liposome‐MTP‐PE in human monocyte activation. Since recombinant human IFN‐γ has a synergistic effect with liposome‐MTP‐PE in monocyte activation, unlike IFN‐α or IFN‐β, and liposome‐MTP‐PE as well as rIFN‐γ is available at standardized concentrations, this combination could be of clinical value in the treatment of disseminated malignant disease.